Department of Cancer Epidemiology, University of Lund, University Hospital, Sweden.
Curr Oncol Rep. 2011 Dec;13(6):433-41. doi: 10.1007/s11912-011-0192-x.
Adjuvant pelvic radiotherapy has the potential to eradicate micrometastases within the irradiated field but has not resulted in survival improvements in randomized studies. This illustrates the need for systemic therapy. Chemotherapy, mainly with anthracyclines, platinum compounds, and taxanes, renders high response rates although this unfortunately translates in only modest improvements in progression-free and overall survival. Better systemic treatments need to be developed. Investigations of the molecular mechanisms of endometrial cancer have identified possible targets for therapy. In advanced endometrial cancer one study shows that chemotherapy is better than whole abdominal radiotherapy, while in the adjuvant situation the combination of chemotherapy and radiotherapy appears promising.
辅助盆腔放疗有可能消灭照射野内的微转移灶,但在随机研究中并未导致生存改善。这说明需要进行系统治疗。化疗主要使用蒽环类药物、铂类化合物和紫杉烷类药物,可实现高缓解率,但不幸的是,这仅使无进展生存期和总生存期略有改善。需要开发更好的系统治疗方法。对子宫内膜癌分子机制的研究已经确定了治疗的可能靶点。在晚期子宫内膜癌中,一项研究表明化疗优于全腹放疗,而在辅助治疗中,化疗联合放疗似乎有前景。